SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending with high anticipation for an imminent NASA Lunar Terrain Vehicle (LTV) contract award, a potential catalyst that the community believes could ignite significant movement. This excitement is fueled by recent analyst upgrades, a broader executive order emphasizing American space superiority, and widespread discussion of a potential short squeeze due to substantial short interest.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Carnival Corp (CCL) is trending due to the highly anticipated reinstatement of its quarterly dividend, coupled with a full-year report detailing record operational performance and investment-grade leverage metrics. The community is overwhelmingly bullish, celebrating this significant turning point as a strong indicator of renewed financial health and a robust outlook for the cruise sector. Despite initial price fluctuations, many investors view this as a clear sign of the company's return to strength and market leadership.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending after reporting an earnings beat that was overshadowed by significant concerns over declining sales in Greater China, pressured gross margins due to tariffs, and a cautious outlook. The community is intensely debating whether the sharp stock decline is an overreaction and a long-term buying opportunity, or if it signals deeper issues for the brand amid stiff competition and shifting consumer sentiment, particularly regarding its China strategy and perceived lack of innovation.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is actively discussed following the launch of its new Predictions platform, marking a strategic expansion into the evolving digital wagering landscape. The community is weighing its market share potential against intensifying competition, while also noting strong recent sports betting performance in key states and increasing regulatory actions against unlicensed prediction market operators. This combination of new product offerings, favorable market dynamics, and a strong operational quarter is driving renewed investor interest.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending following a substantial 10-year colocation agreement for its NC-1 AI data center campus, providing significant long-term revenue visibility. This major deal for AI infrastructure capacity is driving considerable community discussion, with investors highlighting the company's position in a rapidly expanding sector amidst high demand for compute power. Market participants are anticipating enhanced growth and potential for notable stock movement.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending after a robust Q2 earnings beat and a raised fiscal 2026 outlook, fueled by successful cost-cutting initiatives and improved package volumes. Community sentiment is mixed, with bulls celebrating the strong results and analyst upgrades, while skeptics point to ongoing concerns regarding freight operations, global trade headwinds, and the potential for a "sell the news" reaction. As a key transport bellwether, its performance is closely watched for insights into broader logistics sector health.

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Amicus Therapeutics Inc

Amicus Therapeutics ($FOLD) is the subject of widespread discussion following BioMarin Pharmaceutical's announced acquisition for approximately $4.8 billion in cash. The community is reacting strongly, with many celebrating the substantial premium while others voice disappointment, believing the company was acquired for an undervalue. This significant rare disease biotech buyout highlights ongoing M&A trends within the sector.

Starfighters Space Inc

Starfighters Space Inc (FJET) is trending due to its recent IPO, which saw its shares experience significant upward movement, largely attributed to its unique position as the sole commercial entity operating sustained Mach 2 supersonic flights from NASA's Kennedy Space Center. The community is actively discussing the stock's high volatility and trading halts, with many touting its potential as a groundbreaking aerospace player, though some caution about its microcap status and perceived lack of detailed financial transparency.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is a trending topic, with a recent Wedbush downgrade sparking debate on its valuation and future in the evolving mobility sector. While some community members voice concerns over driver compensation and intensified competition, many investors are seizing the opportunity to buy, buoyed by the CEO's share purchases, consistent growth in bookings and riders, and ongoing speculation about strategic partnerships or acquisitions in the autonomous vehicle space.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as excitement builds around its expanded hands-free driving features and robust AI strategy, including custom chips and the anticipated R2 platform. The community is actively discussing recent analyst re-ratings that highlight its long-term potential, fueling a strong "short squeeze" narrative as the stock approaches new highs. This momentum reflects a growing conviction in Rivian's technological advancements and future competitive position in the EV market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday.</li><li>Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin over proposed generic versions of Galafold.</li><li>BioMarin plans to fund the acquisition with a mix of existing cash and about $3.7 billion in new debt</li></ul>Amicus Therapeutics (FOLD) shares jumped more than 30% in on Friday, to their highest level since January 2024, after BioMarin Pharmaceutical (BMRN) agreed to acquire the company in a $4.8 billion all-cash deal.The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday. The transaction is expected to close in the second quarter of fiscal 2026. Biomarin shares gained 6.6%.Both <a href="https://stocktwits.com/symbol/FOLD">FOLD</a> and <a href="https://stocktwits.com/symbol/BMRN">BMRN</a> were among the top trending tickers on Stocktwits.<h2 class="st-heading-2">Portfolio Expansion And Revenue Pipeline</h2>The acquisition will expand BioMarin’s portfolio, adding two new treatments to its existing medicines for rare inherited metabolic disorders.Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease generated $599 million in combined net revenues over the past four quarters. U.S. exclusivity for Galafold is projected through January 2037 following recent patent settlements.The deal is expected to boost revenue as soon as it closes and add to earnings within the first year. BioMarin expects the acquisition to become meaningfully more accretive from 2027.The company plans to fund the acquisition with a mix of existing cash and about $3.7 billion in new debt, with Morgan Stanley providing a bridge financing commitment.<h2 class="st-heading-2">IP Dispute Update</h2>Separately, Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin over proposed generic versions of Galafold. Under the agreements, the companies will be allowed to launch generics in the U.S. starting January 30, 2037, subject to FDA approval.As part of the settlement, all ongoing Hatch-Waxman litigation between the parties will be terminated, and U.S. antitrust authorities will review the agreements.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for Biomarin on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high' message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:904/100;" src="https://news.stocktwits-cdn.com/BMRN_png_a8236939f5.webp" alt="BMRN.png" width="904" height="100"><figcaption>BMRN's Sentiment Meter And Message Volumes at Premarket on Dec. 18, 2025 | Source: Stocktwits</figcaption></figure>One user highlighted the visibility of BMRN’s FY2027 revenue target.<stembedurl>https://stocktwits.com/DairyQueen505/message/639674012</stembedurl>Retail sentiment for Amicus on the platform remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high message volumes.<figure class="image"><img style="aspect-ratio:922/99;" src="https://news.stocktwits-cdn.com/fold_png_a408903f4b.webp" alt="fold.png" width="922" height="99"><figcaption>FOLD's Sentiment Meter and Message Volumes at Premarket on Dec. 18, 2025 | Source: Stocktwits</figcaption></figure>Year-to-date, FOLD stock has gained 15% while BMRN has declined over 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/this-new-product-launch-is-lifting-amesite-shares-premarket/cLeiw0iREs7">This New Product Launch Is Lifting Amesite Shares Premarket — Here’s What Investors Are Watching</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal

The acquisition will add two new treatments to BioMarin’s existing medicines for rare inherited metabolic disorders.

Equity

FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus...

BioMarin To Acquire Amicus Therapeutics For Around $4.8 Bln

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN), a pharmaceutical company, Friday announced that it has entered into a definitive agreement to acquire Amicus Therapeutics (FOLD), a biotech company...

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook BioMarin to Acquire Amicus...

Zacks Industry Outlook Arcutis, Amicus and ANI 

 Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article.


5 Biotech Stocks to Watch for Potential Upside

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector. 

Citigroup Initiates Coverage on Amicus Therapeutics (NASDAQ:FOLD)

Citigroup assumed coverage on Amicus Therapeutics in a research note on Wednesday. They set a "buy" rating and a $17.00 price target for the company...

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?

Amicus hits a 52-week high after an 87.6% six-month surge, driven by strong Galafold sales and rising uptake of Pombiliti + Opfolda.

GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal 

Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.

RCUS Stock Down on Decision to Discontinue GILD Partnered Study 

Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down. 

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Stocktwits Polls

News broke that BioMarin is acquiring the company for $4.8 billion, translating to $14.50 per share in cash, leading to a significant pre-market rally.

Following the buyout news, shares experienced a nearly 30% gain in pre-market trading, positioning it among the top movers.

The acquisition has ignited speculation about which other rare disease biotechnology companies could become the next targets for buyouts.

FOLD
Amicus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FOLD News

FOLDAmicus Therapeutics Inc